A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Molavi B, Rassouli N, Bagwe S, Rasouli N. Central Arkansas Veterans Healthcare System, Little Rock, Arkansas 72205, USA. Vasc Health Risk Manag. 2007;3(6):967-73. PMID: 18200815 The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin. Thiazolidinediones review pubmed search wiki thiazolidinediones Recent Related References: 3D-QSAR Studies on a Series of 5-Arylidine-2, 4-Thiazolidinediones as Aldose Reductase Inhibitors: A Self-Organizing Molecular Field Analysis Approach. Thareja S, Aggarwal S, Bhardwaj TR et al. Med Chem. 2010 Mar 11. PMID: 20218967 Diabetes Medications Related to an Increased Risk of Falls and Fall-Related Morbidity in the Elderly (April). Berlie HD, Garwood CL. Ann Pharmacother. 2010 Mar 9. PMID: 20215495 Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells. Yoshizaki T, Motomura W, Tanno S et al. J Exp Clin Cancer Res. 2010 Mar 10. PMID: 20214829 Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes. Samtani MN. Biopharm Drug Dispos. 2010 Mar 8. PMID: 20213855 A New Concept Underlying Stem Cell Lineage Skewing That Explains the Detrimental Effects of Thiazolidinediones on Bone. Bruedigam C, Eijken M, Koedam M et al. Stem Cells. 2010 Mar 8. PMID: 20213769 Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes: The ACCORD Eye Substudy. Ambrosius WT, Danis RP, Goff DC Jr et al. Arch Ophthalmol. 2010 Mar. PMID: 20212201 Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease. Reilly JB, Berns JS. Semin Dial. 2010 Feb 22. PMID: 20210915 Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone versus Rosiglitazone. Simó R, Rodriguez A, Caveda E. Curr Drug Saf. 2010 Mar 7. PMID: 20210732 Cytokines (interferon-gamma and tumor necrosis factor-alpha)-induced nuclear factor-kappaB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Antonelli A, Ferrari SM, Fallahi P et al. Metabolism. 2010 Mar 5. PMID: 20206950 Rosiglitazone Reduces Plasma Levels of Inflammatory and Hemostatic Biomarkers and Improves Global Endothelial Function in Habitual Heavy Smokers Without Diabetes Mellitus or Metabolic Syndrome. Chen IC, Chao TH, Tsai WC et al. J Formos Med Assoc. 2010 Feb. PMID: 20206835 Self-organizing molecular field analysis of 2,4-thiazolidinediones: A 3D-QSAR model for the development of human PTP1B inhibitors. Thareja S, Aggarwal S, Bhardwaj TR et al. Eur J Med Chem. 2010 Feb 20. PMID: 20236737 Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Barnett AH, Cradock S, Fisher M et al. Int J Clin Pract. 2010 Mar 5. PMID: 20236369 PS2-20: Racial Disparities in A1c Change and Medication Intensification. Rush WA, Crain AL, Amundson GH et al. Clin Med Res. 2010 Mar. PMID: 20305209 [Biomedical research, the market, clinicians, safety and corporate social responsibility post-phase III: Maintaining confidence.] Marín-Gámez N, Kessel-Sardiñas H, Cervantes-Bonet B et al. Rev Calid Asist. 2010 Mar 19. PMID: 20304693 Glucose Supply and Insulin Demand Dynamics of Antidiabetic Agents. Monte SV, Schentag JJ, Adelman MH et al. J Diabetes Sci Technol. 2010 Mar 1. PMID: 20307399 Predictors of Annual Pharmaceutical Costs in Australia for Community-Based Individuals with, or at Risk of, Cardiovascular Disease: Analysis of Australian Data from the REACH Registry. Ademi Z, Liew D, Hollingsworth B et al. Am J Cardiovasc Drugs. 2010 Apr 1. PMID: 20334445 Ensuring integrity in industry-sponsored research: primum non nocere, revisited. DeAngelis CD, Fontanarosa PB. JAMA. 2010 Mar 24. PMID: 20332409 Setting the RECORD Straight. Nissen SE. JAMA. 2010 Mar 24. PMID: 20332408 Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. Wang AT, McCoy CP, Murad MH et al. BMJ. 2010 Mar 18. PMID: 20299696 Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Defronzo RA. Diabetologia. 2010 Apr 2. PMID: 20361178 Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Albers HM, Dong A, van Meeteren LA et al. Proc Natl Acad Sci U S A. 2010 Apr 1. PMID: 20360563 Review article: Thiazolidinediones and heart failure. Chaggar PS, Shaw SM, Williams SG. Diab Vasc Dis Res. 2009 Jul. PMID: 20368206 Review article: Thiazolidinediones and heart failure. Chaggar PS, Shaw SM, Williams SG. Diab Vasc Dis Res. 2009 Jul. PMID: 20368206 Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin. Petrovic V, Costa RH, Lau LF et al. Cancer Biol Ther. 2010 Jun 6. PMID: 20372080 Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy. Barnett AH. Curr Med Res Opin. 2010 Apr 6. PMID: 20370379 In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. Kos K, Wong SP, Huda MS et al. Diabetes Obes Metab. 2010 Apr. PMID: 20380658 In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. Kos K, Wong SP, Huda MS et al. Diabetes Obes Metab. 2010 Apr. PMID: 20380658 Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. Phung OJ, Scholle JM, Talwar M et al. JAMA. 2010 Apr 14. PMID: 20388897 Saxagliptin in type 2 diabetes. Billiones R. Drugs Today (Barc). 2010 Feb. PMID: 20393638 Fibrates, glitazones, and peroxisome proliferator-activated receptors. Lalloyer F, Staels B. Arterioscler Thromb Vasc Biol. 2010 May. PMID: 20393155 Minireview: Nuclear Hormone Receptor 4A Signaling: Implications for Metabolic Disease. Pearen MA, Muscat GE. Mol Endocrinol. 2010 Apr 14. PMID: 20392876 Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice. Duan SZ, Usher MG, Foley EL 4th et al. Diabetologia. 2010 Apr 17. PMID: 20401461 A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy. Raboud JM, Diong C, Carr A et al. HIV Clin Trials. 2010 Jan-Feb. PMID: 20400410 3D-QSAR Studies on a Series of 5-Arylidine-2, 4-Thiazolidinediones as Aldose Reductase Inhibitors: A Self-Organizing Molecular Field Analysis Approach. Thareja S, Aggarwal S, Bhardwaj TR et al. Med Chem. 2010 Jan. PMID: 20402658 Rosiglitazone in the UK: down but not out. Iheanacho I. BMJ. 2010 Apr 7. PMID: 20375092 Rosiglitazone, marketing, and medical science. Moynihan R. BMJ. 2010 Apr 7. PMID: 20375091 Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. Yamanouchi T. Vasc Health Risk Manag. 2010 Apr 15. PMID: 20407626 Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. Glatz T, Stöck I, Nguyen-Ngoc M et al. J Hypertens. 2010 Apr 20. PMID: 20410836 Therapy of nonalcoholic fatty liver disease: current status. Duvnjak M, Tomasic V, Gomercic M et al. J Physiol Pharmacol. 2009 Dec. PMID: 20388946 Therapy of nonalcoholic fatty liver disease: current status. Duvnjak M, Tomasic V, Gomercic M et al. J Physiol Pharmacol. 2009 Dec. PMID: 20388946 Diabetes, insulin, insulin analogues, and cancer. Müssig K, Staiger H, Kantartzis K et al. Dtsch Med Wochenschr. 2010 May. PMID: 20425680 Update on the safety of thiazolidinediones. Lieb DC, McCall AL. Curr Diab Rep. 2010 Apr. PMID: 20425570 Troglitazone, a Ligand of Peroxisome Proliferator-Activated Receptor-{gamma}, Stabilizes NUCB2 (Nesfatin) mRNA by Activating the ERK1/2 Pathway: Isolation and Characterization of the Human NUCB2 Gene. Yamada M, Horiguchi K, Umezawa R et al. Endocrinology. 2010 Apr 28. PMID: 20427483 Glucose control in hospitalized patients. Sawin G, Shaughnessy AF. Am Fam Physician. 2010 May 1. PMID: 20433128 NASH: Thiazolidinediones for NASH--one pill doesn't fix everything. Neuschwander-Tetri BA. Nat Rev Gastroenterol Hepatol. 2010 May. PMID: 20442730 Composite end points in clinical trials. Sheehe PR. JAMA. 2010 May 5. PMID: 20442384 Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. Kaul S, Bolger AF, Herrington D et al. J Am Coll Cardiol. 2010 Apr 27. PMID: 20413044 Effects of long-term pioglitazone treatment on peripheral and central markers of aging. Blalock EM, Phelps JT, Pancani T et al. PLoS One. 2010 Apr 29. PMID: 20454453 Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Eto K, Tumenbayar B, Nagashima SI et al. Diabetes Res Clin Pract. 2010 May 6. PMID: 20452080 What is the best management strategy for patients with severe insulin resistance? Semple RK, Williams R, Dunger DB. Clin Endocrinol (Oxf). 2010 Apr 23. PMID: 20455892 Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 Diabetes (June) (CE). Borja-Hart NL, Whalen KL. Ann Pharmacother. 2010 May 11. PMID: 20460554 Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: Data from a randomized, placebo-controlled, double-blind study. Walcher T, Walcher D, Hetzel J et al. Diab Vasc Dis Res. 2010 May 11. PMID: 20460360 Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database. Zhang Q, Mavros P, Engel SS et al. Curr Med Res Opin. 2010 May 13. PMID: 20465367 Managing type 2 diabetes: balancing HbA1c and body weight. Mavian AA, Miller S, Henry RR. Postgrad Med. 2010 May. PMID: 20463420 New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals. Wysham CH. Postgrad Med. 2010 May. PMID: 20463414 Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Derosa G, Maffioli P. Diabetes Technol Ther. 2010 Jun. PMID: 20470234 Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Tilg H, Moschen A. Minerva Gastroenterol Dietol. 2010 Jun. PMID: 20485253 The Effect of Oral Antidiabetic Agents on Glycated Hemoglobin Levels: A Systematic Review and Meta-Analysis. Sherifali D, Nerenberg K, Pullenayegum E et al. Diabetes Care. 2010 May 18. PMID: 20484130 Hydrochloride pioglitazone decreases urinary TGF-beta1 excretion in type 2 diabetics. Hu YY, Ye SD, Zhao LL et al. Eur J Clin Invest. 2010 May 17. PMID: 20482594 Treatment of dyslipidemia in HIV-infected patients. Sekhar RV, Balasubramanyam A. Expert Opin Pharmacother. 2010 May 20. PMID: 20486828 Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of PPAR{gamma} activation in mice. Huo Y, Guo X, Xu K et al. J Biol Chem. 2010 May 24. PMID: 20498376 Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option? Säemann MD, Krebs M. Wien Klin Wochenschr. 2010 Apr. PMID: 20503018 Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4. Arbones-Mainar JM, Johnson LA, Altenburg MK et al. FASEB J. 2010 May 25. PMID: 20501792 High-Sensitivity C-Reactive Protein Predicts Cardiovascular Risk in Diabetic and Nondiabetic Patients: Effects of Insulin-Sensitizing Treatment with Pioglitazone. Pfützner A, Schöndorf T, Hanefeld M et al. J Diabetes Sci Technol. 2010 May 1. PMID: 20513338 Rosiglitazone Attenuates Endothelin-1-Induced Vasoconstriction by Upregulating Endothelial Expression of Endothelin B Receptor. Tian J, Wong WT, Tian XY et al. Hypertension. 2010 Jun 1. PMID: 20516393 Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? Campbell IW. Int J Clin Pract. 2010 May. PMID: 20518953 Pathophysiology of diabetes in elderly people. Paolisso G. Acta Biomed. 2010. PMID: 20518191 GSK is accused of trying to suppress editorial on rosiglitazone. Tanne JH. BMJ. 2010 May 19. PMID: 20484354 An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells. Sturek JM, Castle JD, Trace AP et al. J Clin Invest. 2010 Jun 7. PMID: 20530872 Thiazolinedione treatment in PCOS - an update. Glintborg D, Andersen M. Gynecol Endocrinol. 2010 Jun 9. PMID: 20528570 Discovery and Optimization of Boronic Acid Based Inhibitors of Autotaxin. Albers HM, van Meeteren LA, Egan DA et al. J Med Chem. 2010 Jun 10. PMID: 20536182 Thiazolidinediones as a Novel Class of Algicides Against Red Tide Harmful Algal Species. Kim YM, Wu Y, Duong TU et al. Appl Biochem Biotechnol. 2010 Jun 11. PMID: 20544303 Novel treatment modalities for Graves' orbitopathy. Bartalena L, Lai A, Sassi L et al. Pediatr Endocrinol Rev. 2010 Mar. PMID: 20467365 Diabetes mellitus, hyperglycaemia and cancer. Simon D, Balkau B. Diabetes Metab. 2010 May 27. PMID: 20554237 Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Yu J, Shen B, Chu ES et al. Hepatology. 2010 Jun. PMID: 20512989 Colon OCTN2 gene expression is up-regulated by PPAR{gamma} in humans and mice, and contributes to local and systemic carnitine homeostasis. D'Argenio G, Petillo O, Margarucci S et al. J Biol Chem. 2010 Jun 17. PMID: 20558736 Comparison of Pioglitazone vs Glyburide in Early Heart Failure: Insights From a Randomized Controlled Study of Patients With Type 2 Diabetes and Mild Cardiac Disease. Giles TD, Elkayam U, Bhattacharya M et al. Congest Heart Fail. 2010 May 1. PMID: 20557330 Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues. Mitka M. JAMA. 2010 Jun 16. PMID: 20551399 Avandia outcome may signal change in epidemiologists' sway. Wadman M. Nat Med. 2010 Jun. PMID: 20526293 GlaxoSmithKline denies it has settled thousands of lawsuits over rosiglitazone (Avandia). Tanne JH. BMJ. 2010 Jun 7. PMID: 20530068 A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Musso G, Gambino R, Cassader M et al. Hepatology. 2010 Mar 1. PMID: 20578268 Pharmacologic Prophylaxis of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Beyond beta-Blockers. Davis EM, Packard KA, Hilleman DE. Pharmacotherapy. 2010 Jul. PMID: 20575638 Bone loss and fracture risk associated with thiazolidinedione therapy. Riche DM, Travis King S. Pharmacotherapy. 2010 Jul. PMID: 20575635 Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD). Bilik D, McEwen LN, Brown MB et al. Pharmacoepidemiol Drug Saf. 2010 May 17. PMID: 20583206 Pioglitazone in chemically induced mammary carcinogenesis in rats. Bojková B, Garajová M, Kajo K et al. Eur J Cancer Prev. 2010 Jun 24. PMID: 20581687 Rosiglitazone, thiazolidinediones and atherosclerosis. Dandona P, Chaudhuri A, Ghanim H. Atherosclerosis. 2010 Jun 8. PMID: 20580364 Diabetes: making sense of the rosiglitazone controversy. Farkouh ME, Fuster V. Nat Rev Cardiol. 2010 Jul. PMID: 20577297 Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. Botton T, Puissant A, Cheli Y et al. Cell Death Differ. 2010 Jul 2. PMID: 20596077 A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. McEwan P, Evans M, Bergenheim K. Diabetes Obes Metab. 2010 Jul. PMID: 20590737 Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: Implications for the evaluation of antidiabetic drugs. Gerstein HC, Yusuf S. Am Heart J. 2010 Jul. PMID: 20598964 Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Hsiao FY, Tsai YW, Wen YW et al. Pharmacoepidemiol Drug Saf. 2010 Jul 2. PMID: 20607752 Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors. Pavlov TS, Imig JD, Staruschenko A. PPAR Res. 2010. PMID: 20613963 Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects. Bocciardi R, Ravazzolo R. PPAR Res. 2010. PMID: 20613955 Lipid-induced insulin resistance: unravelling the mechanism. Samuel VT, Petersen KF, Shulman GI. Lancet. 2010 Jun 26. PMID: 20609972 [Diabetes mellitus, thiazolidinediones and fractures: an unfinished story.] Silva AG, Lazaretti-Castro M. Arq Bras Endocrinol Metabol. 2010 Jun. PMID: 20625645 Study confirms link between certain diabetes drugs and fractures. . Harv Womens Health Watch. 2010 May. PMID: 20593558 Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes. Bilik D, McEwen LN, Brown MB et al. J Clin Endocrinol Metab. 2010 Jul 14. PMID: 20631021 Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, Xie C, Do R et al. Diabetes Care. 2010 Jul 13. PMID: 20628086 Interventional studies for polycystic ovarian syndrome in children and adolescents. Vuguin PM. Ped Health. 2010 Feb. PMID: 20640230 Diabetic Macular Edema: Correlations with Available Diabetes Therapies - Evidence Across a Qualitative Review of Published Literature from MEDLINE and EMBASE. Merante D, Menchini F, Truitt KE et al. Drug Saf. 2010 Aug 1. PMID: 20635822 Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Waugh N, Cummins E, Royle P et al. Health Technol Assess. 2010 Jul. PMID: 20646668 Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study. Banerji MA, Purkayastha D, Francis BH. Diabetes Res Clin Pract. 2010 Jul 22. PMID: 20655609 Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression. Mabilleau G, Mieczkowska A, Edmonds ME. Diabet Med. 2010 Aug. PMID: 20653751 FDA committee urges tight restrictions on rosiglitazone. Roehr B. BMJ. 2010 Jul 16. PMID: 20639290 Intracellular Ca2+ can compensate for the lack of NADPH oxidase-derived ROS in endothelial cells. Lee M, Spokes KC, Aird WC et al. FEBS Lett. 2010 Jul 16. PMID: 20621840 Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4-thiazolidinedione derivatives. Patil V, Tilekar K, Mehendale-Munj S et al. Eur J Med Chem. 2010 Jul 11. PMID: 20667627 Synthesis and primary cytotoxicity evaluation of new 5-benzylidene-2,4-thiazolidinedione derivatives. Patil V, Tilekar K, Mehendale-Munj S et al. Eur J Med Chem. 2010 Jul 11. PMID: 20667627 PPARgamma and chronic kidney disease. Fogo AB. Pediatr Nephrol. 2010 Jul 30. PMID: 20676693 Thiazolidinediones and cardiovascular risk - a question of balance. Erdmann E, Charbonnel B, Wilcox R. Curr Cardiol Rev. 2009 Aug. PMID: 20676274 Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin. Galli A, Ceni E, Mello T et al. Hepatology. 2010 Aug. PMID: 20683949 Synthesis and antidiabetic activity of some new chromonyl-2,4-thiazolidinediones. Ceylan-Ünlüsoy M, Verspohl EJ, Ertan R. J Enzyme Inhib Med Chem. 2010 Aug 5. PMID: 20687791 Long-Term Effects of Pioglitazone on Carotid Atherosclerosis in Japanese Patients with Type 2 Diabetes without a Recent History of Macrovascular Morbidity. Yamasaki Y, Katakami N, Furukado S et al. J Atheroscler Thromb. 2010 Jul 31. PMID: 20686324 Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion. Gamboa J, Blankenship D, Niemi JP et al. Neuroscience. 2010 Aug 4. PMID: 20691766 Dipeptidylpeptitase-4 inhibitors (gliptins): focus on drug-drug interactions. Scheen AJ. Clin Pharmacokinet. 2010 Sep 1. PMID: 20690781 FDA puts rosiglitazone post-marketing trial on hold. Cohen D. BMJ. 2010 Jul 26. PMID: 20660507 Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease. Siew ED, Ikizler TA. Semin Dial. 2010 Jul. PMID: 20701717 Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. Shi L, Zhao Y, Szymanski K et al. J Diabetes Complications. 2010 Aug 11. PMID: 20708416 Avandia panel member may be investigated for possible conflicts of interest. Tanne JH. BMJ. 2010 Aug 3. PMID: 20682621 Incretin-Based Therapies: Review of the Outpatient Literature with Implications for Use in the Hospital and After Discharge. Bode B Md, Amin A Md. Hosp Pract (Minneap). 2009 Dec. PMID: 20720383 The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. Nicolakakis N, Hamel E. Front Aging Neurosci. 2010 May 21. PMID: 20725514 Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Katsiki N, Hatzitolios AI. Curr Opin Obstet Gynecol. 2010 Aug 18. PMID: 20724929 Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience. Foley JE, Jordan J. Vasc Health Risk Manag. 2010 Aug 9. PMID: 20730070 Risk of Cardiovascular Events and All-Cause Mortality in Patients Treated With Thiazolidinediones in a Managed-Care Population. Wertz DA, Chang CL, Sarawate CA et al. Circ Cardiovasc Qual Outcomes. 2010 Aug 24. PMID: 20736441 Risk of Cardiovascular Events and All-Cause Mortality in Patients Treated With Thiazolidinediones in a Managed-Care Population. Wertz DA, Chang CL, Sarawate CA et al. Circ Cardiovasc Qual Outcomes. 2010 Aug 24. PMID: 20736441 Stimulation of ENaC Activity by Rosiglitazone is PPARgamma-Dependent and Correlates with SGK1 Expression Increase. Renauld S, Tremblay K, Ait-Benichou S et al. J Membr Biol. 2010 Aug 26. PMID: 20740360 Epinephrine Mediated Regulation of PDK4 mRNA in Rat Adipose Tissue. Wan Z, Thrush AB, Legare M et al. Am J Physiol Cell Physiol. 2010 Aug 25. PMID: 20739620 Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. Dunn FL, Higgins LS, Fredrickson J et al. J Diabetes Complications. 2010 Aug 23. PMID: 20739195 Modulation of Pantothenate Kinase 3 Activity by Small Molecules that Interact with the Substrate/Allosteric Regulatory Domain. Leonardi R, Zhang YM, Yun MK et al. Chem Biol. 2010 Aug 27. PMID: 20797618 Modulation of Pantothenate Kinase 3 Activity by Small Molecules that Interact with the Substrate/Allosteric Regulatory Domain. Leonardi R, Zhang YM, Yun MK et al. Chem Biol. 2010 Aug 27. PMID: 20797618 Cytotoxic effects of statins and thiazolidinediones on meningioma cells. Gehring S, Tapia-Pérez JH, Kirches E et al. J Neurooncol. 2010 Aug 30. PMID: 20803306 Is there a role for the nuclear receptor PPARgamma in neuropsychiatric diseases? García-Bueno B, Pérez-Nievas BG, Leza JC. Int J Neuropsychopharmacol. 2010 Aug 27. PMID: 20800014 Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Kurukulasuriya LR, Sowers JR. Cardiovasc Diabetol. 2010 Aug 30. PMID: 20804556 Mistletoe lectin-I augments antiproliferative effects of the PPARgamma agonist rosiglitazone on human malignant melanoma cells. Freudlsperger C, Dahl A, Hoffmann J et al. Phytother Res. 2010 Sep. PMID: 20812278 In Vitro Evaluation of Inhibitory Effects of Antidiabetic and Antihyperlipidemic Drugs on Human Carboxylesterase Activities. Fukami T, Takahashi S, Nakagawa N et al. Drug Metab Dispos. 2010 Sep 1. PMID: 20810539 Mechanisms of adiponectin regulation and use as a pharmacological target. Phillips SA, Kung JT. Curr Opin Pharmacol. 2010 Aug 30. PMID: 20810317 Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis. Lecka-Czernik B. Curr Osteoporos Rep. 2010 Sep 1. PMID: 20809203